CITA Biomedical Begins Executive Search
BEVERLY HILLS, Calif., Dec. 13 /PRNewswire-FirstCall/ -- CITA Biomedical, Inc. (CITA) (OTC Bulletin Board: DTOX) a growing leader in the treatment of substance dependency, today announced that the search has begun for a new president and chief financial officer (CFO) to replace the departing president, Steven J. Rutlen and CFO, John Peters.
Both Mr. Rutlen and Mr. Peters are leaving CITA to pursue opportunities that are more inline with their interests and goals. CITA is aggressively working on recruiting top executives with experience in building companies and managing them through rapid growth. In the interim Joseph Dunn, chairman and CEO of CITA Biomedical will serve as president and CFO.
About CITA Biomedical, Inc.
CITA Biomedical, Inc., headquartered in Beverly Hills, Calif., focuses on the innovative treatment of addiction. The company holds the U.S. patent for its successful UROD (Ultra Rapid Opiate Detoxification) treatment method. UROD is the only clinically tested and effective treatment method to rapidly detoxify individuals addicted to opiate-based drugs, including heroin within four to six hours with few, if any, withdrawal symptoms. The company has a new family of revolutionary treatments, Detoxification and NeuroAdaptation (DNA) for Addictions. The first treatments from this family treat alcohol, cocaine, crack, and poly-drug addictions. To date, CITA has grown its business through internal expansion and now seeks compatible, leading, and complementing technologies and acquisitions to enhance its corporate portfolio. CITA Biomedical, Inc. has two operating divisions CITA Americas, Inc., and AltTPro, Inc. For more information, please visit www.citabio.com
UROD is a registered trademark of CITA Biomedical, Inc.
The information contained in this press release includes forward-looking statements. Forward-looking statements include declarations concerning plans, objectives, goals, strategies, future events and/or performance, and underlying assumptions and other statements which are other than statements of historical facts. Forward-looking statements usually contain the words "estimate," "anticipate," "believe," "expect" and other similar expressions that involve risks and uncertainties. These risks and uncertainties include, but are not limited to, the Company's status as a start-up enterprise with uncertain profitability, its need for significant capital, limited facilities, competition, uncertainty as to market acceptance of its services, and the protection of its intellectual property. The Company's actual results could differ materially from those expressed or implied in any forward-looking statements.
Contacts:
Investor Relations Treatment Information
CITA Biomedical, Inc. Call: 1-888-400-2482
Judy Ryon, 310-550-4971 or
jryon@citabio.com Visit: www.citatreatment.com
SOURCE CITA Biomedical, Inc.
CONTACT: Judy Ryon of CITA Biomedical, Inc., +1-310-550-4971,
jryon@citabio.com, or CITA Biomedical Treatment Information, +1-888-400-2482
Web site: citabio.com
citatreatment.com |
